Thromboembolic events in pregnancy: pharmacological prophylaxis and treatment.
Pregnancy-associated arterial and venous thromboembolism continue to be significant causes of maternal mortality and morbidity. Many of these deaths are potentially avoidable by better identification of risk, optimal prophylaxis and management of thromboembolic complications. This review aims to describe the recent developments in pharmacological thromboprophylaxis and acute treatment of arterial and venous thromboembolism in pregnancy.
Nelson
Scott M
SM
University of Glasgow, Reproductive and Maternal Medicine, Division of Developmental Medicine, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER, UK. s.nelson@clinmed.gla.ac.uk
Greer
Ian A
IA
D000925:Anticoagulants / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D008019:Life Style; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D018570:Risk Assessment; D012307:Risk Factors; D053828:Stockings, Compression; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors